Elizabeth Carpenter
Elizabeth Carpenter serves as executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Elizabeth joined PhRMA from Avalere, where she spent 10 years, most recently as President. Prior to joining Avalere, Elizabeth was a senior advisor in the Health Policy practice at McKenna Long & Aldridge LLP, where she provided government affairs and public policy support to payers, providers, private exchanges, and states on a wide-range of health policy and political issues. Previously, she served as the associate policy director for the Health Policy Program at the New America Foundation where she led Congressional and media relations during the debate over the ACA and provided educational and technical support to stakeholders, members of Congress, and the media. Elizabeth started her career on Capitol Hill on the legislative and campaign staffs of Senator Lincoln Chafee (RI).
Elizabeth Carpenter serves as executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Elizabeth joined PhRMA from Avalere, where she spent 10 years, most recently as President. Prior to joining Avalere, Elizabeth was a senior advisor in the Health Policy practice at McKenna Long & Aldridge LLP, where she provided government affairs and public policy support to payers, providers, private exchanges, and states on a wide-range of health policy and political issues. Previously, she served as the associate policy director for the Health Policy Program at the New America Foundation where she led Congressional and media relations during the debate over the ACA and provided educational and technical support to stakeholders, members of Congress, and the media. Elizabeth started her career on Capitol Hill on the legislative and campaign staffs of Senator Lincoln Chafee (RI).
Articles: Elizabeth Carpenter
Extraordinary Strides Against Breast Cancer Mortality Underscore Strengths of the US Approach to Innovation
USA / As Breast Cancer Awareness Month 2024 draws to a close, PhRMA’s Elizabeth Carpenter lays out the massive progress made in breast cancer treatment outcomes over the past half-century. However, Carpenter warns that further progress in breast cancer R&D is under threat, highlighting three key policy barriers that must be removed to ensure cutting-edge treatments continue…
Latest Report
